Aly Karsan
YOU?
Author Swipe
View article: Loss of FBXO11 establishes a stem cell program in acute myeloid leukemia by dysregulating LONP1
Loss of FBXO11 establishes a stem cell program in acute myeloid leukemia by dysregulating LONP1 Open
Acute myeloid leukemia (AML) is an aggressive cancer with very poor outcomes. To identify additional drivers of leukemogenesis, we analyzed sequencing data from 1,727 unique individual AML patients, which revealed mutations in ubiquitin li…
View article: Patient and population impacts of multigene panel and pembrolizumab coverage in metastatic melanoma
Patient and population impacts of multigene panel and pembrolizumab coverage in metastatic melanoma Open
Background Targeted treatment or immunotherapy may yield increased, durable responses for melanoma patients. Whether patient-level benefits translate to population health is unknown. This study sought to estimate patient and population imp…
View article: Outcomes following MRD relapse in AML patients monitored by droplet digital PCR
Outcomes following MRD relapse in AML patients monitored by droplet digital PCR Open
Introduction: European Leukemia Network (ELN) guidelines recommend PCR-based measurable residual disease (MRD) monitoring for patients with acute myeloid leukemia (AML) with NPM1 mutation (NPM1mut), t(8;21)/RUNX1::RUNX1T1 or inv(16)/CBFB::…
View article: Supplemental Table 1 from Clonal Hematopoiesis of Indeterminate Potential and its Association with Treatment Outcomes and Adverse Events in Patients with Solid Tumors
Supplemental Table 1 from Clonal Hematopoiesis of Indeterminate Potential and its Association with Treatment Outcomes and Adverse Events in Patients with Solid Tumors Open
TRIPOD checklist
View article: Supplemental Table 2 from Clonal Hematopoiesis of Indeterminate Potential and its Association with Treatment Outcomes and Adverse Events in Patients with Solid Tumors
Supplemental Table 2 from Clonal Hematopoiesis of Indeterminate Potential and its Association with Treatment Outcomes and Adverse Events in Patients with Solid Tumors Open
All CHIP variants identified in the study
View article: Supplemental Figure 2 from Clonal Hematopoiesis of Indeterminate Potential and its Association with Treatment Outcomes and Adverse Events in Patients with Solid Tumors
Supplemental Figure 2 from Clonal Hematopoiesis of Indeterminate Potential and its Association with Treatment Outcomes and Adverse Events in Patients with Solid Tumors Open
Progression free survival for patients on PREDiCT-l, split by tumor type. Therapy received is indicated in each title above each Kaplan Meier curve.
View article: Supplemental Figure 1 from Clonal Hematopoiesis of Indeterminate Potential and its Association with Treatment Outcomes and Adverse Events in Patients with Solid Tumors
Supplemental Figure 1 from Clonal Hematopoiesis of Indeterminate Potential and its Association with Treatment Outcomes and Adverse Events in Patients with Solid Tumors Open
VAF of all CHIP variants split by cohort
View article: Predisposition to hematopoietic malignancies by deleterious germline CHEK2 variants
Predisposition to hematopoietic malignancies by deleterious germline CHEK2 variants Open
The role of germline CHEK2 variants in hematopoietic malignancies (HMs) is poorly understood. We examined pathogenic/likely pathogenic (P/LP) CHEK2 variants in patients with hereditary HMs (HHMs), a solid tumor risk cohort, public datasets…
View article: Haploinsufficiency of miR-143 and miR-145 reveal targetable dependencies in resistant del(5q) myelodysplastic neoplasm
Haploinsufficiency of miR-143 and miR-145 reveal targetable dependencies in resistant del(5q) myelodysplastic neoplasm Open
Myelodysplastic neoplasms (MDS) are stem cell disorders characterized by ineffective hematopoiesis and risk of transformation to acute myeloid leukemia (AML). Chromosomal alterations are frequent in MDS, with interstitial deletion of chrom…
View article: Clinical Effectiveness and Cost-Effectiveness of Multigene Panel Sequencing in Advanced Melanoma: A Population-Level Real-World Target Trial Emulation
Clinical Effectiveness and Cost-Effectiveness of Multigene Panel Sequencing in Advanced Melanoma: A Population-Level Real-World Target Trial Emulation Open
PURPOSE Targeted therapy and immunotherapy promise improved survival in patients with advanced melanoma, yet the effectiveness and cost-effectiveness of multigene panel sequencing compared with single-gene BRAF testing to guide therapeutic…
View article: Supplemental Table 2 from Clonal Hematopoiesis of Indeterminate Potential and its Association with Treatment Outcomes and Adverse Events in Patients with Solid Tumors
Supplemental Table 2 from Clonal Hematopoiesis of Indeterminate Potential and its Association with Treatment Outcomes and Adverse Events in Patients with Solid Tumors Open
All CHIP variants identified in the study
View article: Figure 3 from Clonal Hematopoiesis of Indeterminate Potential and its Association with Treatment Outcomes and Adverse Events in Patients with Solid Tumors
Figure 3 from Clonal Hematopoiesis of Indeterminate Potential and its Association with Treatment Outcomes and Adverse Events in Patients with Solid Tumors Open
CHIP and treatment outcomes. Kaplan–Meier curves showing the difference in outcome between patients with (CHIP+) and without CHIP (CHIP−) and outcomes on different therapies. PFS is shown on the left two columns for all three cohorts, and …
View article: Figure 1 from Clonal Hematopoiesis of Indeterminate Potential and its Association with Treatment Outcomes and Adverse Events in Patients with Solid Tumors
Figure 1 from Clonal Hematopoiesis of Indeterminate Potential and its Association with Treatment Outcomes and Adverse Events in Patients with Solid Tumors Open
Consort diagram and reasons for exclusion.
View article: Data from Clonal Hematopoiesis of Indeterminate Potential and its Association with Treatment Outcomes and Adverse Events in Patients with Solid Tumors
Data from Clonal Hematopoiesis of Indeterminate Potential and its Association with Treatment Outcomes and Adverse Events in Patients with Solid Tumors Open
Clonal hematopoiesis of indeterminate potential (CHIP) is the clonal expansion of hematopoietic stem cells from somatic mutations. It is a common incidental finding in cell-free DNA (cfDNA). We investigated the incidence of CHIP in cfDNA f…
View article: Table 1 from Clonal Hematopoiesis of Indeterminate Potential and its Association with Treatment Outcomes and Adverse Events in Patients with Solid Tumors
Table 1 from Clonal Hematopoiesis of Indeterminate Potential and its Association with Treatment Outcomes and Adverse Events in Patients with Solid Tumors Open
Baseline characteristics of the included patients
View article: Figure 2 from Clonal Hematopoiesis of Indeterminate Potential and its Association with Treatment Outcomes and Adverse Events in Patients with Solid Tumors
Figure 2 from Clonal Hematopoiesis of Indeterminate Potential and its Association with Treatment Outcomes and Adverse Events in Patients with Solid Tumors Open
Prevalence of CHIP variants across cohorts and CHIP association with age. A, Percentage of patients with CHIP variants in each cohort. Insert shows the breakdown by tumor type in the PREDiCT-l cohort. B, Number of patients with a CHIP vari…
View article: Supplemental Figure 2 from Clonal Hematopoiesis of Indeterminate Potential and its Association with Treatment Outcomes and Adverse Events in Patients with Solid Tumors
Supplemental Figure 2 from Clonal Hematopoiesis of Indeterminate Potential and its Association with Treatment Outcomes and Adverse Events in Patients with Solid Tumors Open
Progression free survival for patients on PREDiCT-l, split by tumor type. Therapy received is indicated in each title above each Kaplan Meier curve.
View article: Figure 4 from Clonal Hematopoiesis of Indeterminate Potential and its Association with Treatment Outcomes and Adverse Events in Patients with Solid Tumors
Figure 4 from Clonal Hematopoiesis of Indeterminate Potential and its Association with Treatment Outcomes and Adverse Events in Patients with Solid Tumors Open
CHIP and adverse events. A, Percentage of patients on each treatment that had an adverse event on therapy, split by cohort and treatment. B, Proportions of patients with adverse events split by CHIP status. Lighter shades indicate no adver…
View article: Supplemental Figure 1 from Clonal Hematopoiesis of Indeterminate Potential and its Association with Treatment Outcomes and Adverse Events in Patients with Solid Tumors
Supplemental Figure 1 from Clonal Hematopoiesis of Indeterminate Potential and its Association with Treatment Outcomes and Adverse Events in Patients with Solid Tumors Open
VAF of all CHIP variants split by cohort
View article: Supplemental Table 1 from Clonal Hematopoiesis of Indeterminate Potential and its Association with Treatment Outcomes and Adverse Events in Patients with Solid Tumors
Supplemental Table 1 from Clonal Hematopoiesis of Indeterminate Potential and its Association with Treatment Outcomes and Adverse Events in Patients with Solid Tumors Open
TRIPOD checklist
View article: Clonal Hematopoiesis of Indeterminate Potential and its Association with Treatment Outcomes and Adverse Events in Patients with Solid Tumors
Clonal Hematopoiesis of Indeterminate Potential and its Association with Treatment Outcomes and Adverse Events in Patients with Solid Tumors Open
Clonal hematopoiesis of indeterminate potential (CHIP) is the clonal expansion of hematopoietic stem cells from somatic mutations. It is a common incidental finding in cell-free DNA (cfDNA). We investigated the incidence of CHIP in cfDNA f…
View article: Real-world cost-effectiveness of multi-gene panel sequencing to inform therapeutic decisions for advanced non-small cell lung cancer: a population-based study
Real-world cost-effectiveness of multi-gene panel sequencing to inform therapeutic decisions for advanced non-small cell lung cancer: a population-based study Open
This research was supported by Genome British Columbia/Genome Canada (G05CHS) and the Terry Fox Research Institute.
View article: Supplementary Table S2 from Targeting BET proteins downregulates miR-33a to promote synergy with PIM inhibitors in CMML
Supplementary Table S2 from Targeting BET proteins downregulates miR-33a to promote synergy with PIM inhibitors in CMML Open
References used for filtering hits from drug screen
View article: Supplementary Data S2 from Targeting BET proteins downregulates miR-33a to promote synergy with PIM inhibitors in CMML
Supplementary Data S2 from Targeting BET proteins downregulates miR-33a to promote synergy with PIM inhibitors in CMML Open
Raw RNAseq data corresponding to Figures 2C, 4D and Supplemental Figure 2B
View article: Supplementary Figure S3 from Targeting BET proteins downregulates miR-33a to promote synergy with PIM inhibitors in CMML
Supplementary Figure S3 from Targeting BET proteins downregulates miR-33a to promote synergy with PIM inhibitors in CMML Open
Supplemental Figure 3 shows endogenous PIM1 levels in SKM1 WT and overexpressing cells and BETi/PIMi sensitivity correlation in PIM1 overexpressing cells.